You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Market News

Market News

HomeMarket NewsInformation about Individual Stocks

HANXBIO-B (03378)

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. develops and manufactures immunotherapies for cancer and autoimmune diseases. The company's products include antibody drugs, including monoclonal, bispecific, and antibody drug conjugates for immuno-oncology pathways. The company was incorporated in 2014 and is headquartered in Wuhan, China.